Bristol-Myers, Ono, Bayer Team Up For Colorectal Cancer Study
Zacks Investment Research | Jul 18, 2019 10:32PM ET
Bristol-Myers Squibb Company (NYSE:BMY) along with Japan’s Ono Pharmaceutical and Bayer (DE:BAYGN) AG (OTC:BAYRY) has entered into a collaboration agreement to evaluate the combination of Bristol-Myers’ PD-L1 inhibitor Opdivo (nivolumab) plus Bayer’s Stivarga (regorafenib) for treating patients with microsatellite-stable metastatic colorectal cancer (MSS mCRC), the most common type of CRC.
With this deal, the three companies are looking to evaluate the combination of Opdivo + Stivarga compared to Stivarga alone for treating the given indication. The financial terms of the deal have been kept under wraps.
Stivarga as a monotherapy demonstrated an overall survival benefit compared to placebo in the pivotal phase III CORRECT study. However, despite progress in the treatment and current approvals for the drug, MSS mCRC remains difficult to treat. As a result, combination treatment options become imperative. The combination of Opdivo + Stivarga has shown promising preliminary efficacy results in a phase Ib REGONIVO study conducted in Japan. Data from the study was recently presented at the annual meeting of American Society of Clinical Oncology.
Shares of Bristol-Myers have lost 15.3% so far this year, underperforming the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.